These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34614513)

  • 1. Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia.
    Herishanu Y; Avivi I; Levi S; Shefer G; Bronstein Y; Moshiashvili MM; Ziv T; Scarfò L; Perry C; Ghia P
    Blood Adv; 2022 Jan; 6(1):148-151. PubMed ID: 34614513
    [No Abstract]   [Full Text] [Related]  

  • 2. T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial.
    Blixt L; Wullimann D; Aleman S; Lundin J; Chen P; Gao Y; Cuapio A; Akber M; Lange J; Rivera-Ballesteros O; Buggert M; Ljunggren HG; Hansson L; Österborg A
    Haematologica; 2022 Apr; 107(4):1000-1003. PubMed ID: 35045694
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study.
    Molica S; Giannarelli D; Lentini M; Zappala D; Mannella A; Loiacono D; Gianfelici V; Panduri G; Gariani I; Minchella P; Talarico F; Levato L
    Chemotherapy; 2022; 67(2):91-95. PubMed ID: 34872098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia.
    Bagacean C; Letestu R; Al-Nawakil C; Brichler S; Lévy V; Sritharan N; Delmer A; Dartigeas C; Leblond V; Roos-Weil D; Tomowiak C; Merabet F; Béné MC; Clavert A; Chaoui D; Genet P; Guieze R; Laribi K; Drénou B; Willems L; Puppinck C; Legendre H; Troussard X; Malartre S; Cymbalista F; Michallet AS
    Blood Adv; 2022 Jan; 6(1):207-211. PubMed ID: 34844264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study.
    Olariu TR; Ursoniu S; Marincu I; Lupu MA
    Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946275
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
    Herishanu Y; Avivi I; Aharon A; Shefer G; Levi S; Bronstein Y; Morales M; Ziv T; Shorer Arbel Y; Scarfò L; Joffe E; Perry C; Ghia P
    Blood; 2021 Jun; 137(23):3165-3173. PubMed ID: 33861303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months.
    Ponticelli D; Antonazzo IC; Caci G; Vitale A; Della Ragione G; Romano ML; Borrelli M; Schiavone B; Polosa R; Ferrara P
    J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34697627
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
    Benjamini O; Rokach L; Itchaki G; Braester A; Shvidel L; Goldschmidt N; Shapira S; Dally N; Avigdor A; Rahav G; Lustig Y; Ben David SS; Fineman R; Paz A; Bairey O; Polliack A; Levy I; Tadmor T
    Haematologica; 2022 Mar; 107(3):625-634. PubMed ID: 34320789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serological response following vaccination with BNT162b2 mRNA in patients with chronic lymphocytic leukemia.
    da Cunha-Bang C; Kirkby NS; Friis-Hansen L; Niemann CU
    Leuk Lymphoma; 2022 Feb; 63(2):503-505. PubMed ID: 34727829
    [No Abstract]   [Full Text] [Related]  

  • 10. [Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination].
    Matsumura A; Katsuki K; Akimoto M; Sakuma T; Nakajima Y; Miyazaki T; Fujisawa S; Nakajima H
    Rinsho Ketsueki; 2021; 62(11):1639-1642. PubMed ID: 34866090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current perspectives regarding SARS-CoV-2 vaccination in chronic lymphocytic leukemia.
    Molica S; Tam C; Polliack A
    Hematol Oncol; 2022 Aug; 40(3):313-319. PubMed ID: 35304771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety Profile and Low Risk of Disease Relapse After BNT162b2 mRNA SARS-CoV-2 Vaccination in Patients With Rare Rheumatic Diseases.
    Fornaro M; Venerito V; Iannone F; Cacciapaglia F
    J Rheumatol; 2022 Mar; 49(3):334-335. PubMed ID: 35033998
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and BNT162b2 mRNA COVID-19 vaccination.
    Joob B; Wiwanitkit V
    Acta Biomed; 2022 Jan; 92(6):e2021485. PubMed ID: 35075060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-episodic angioedema with eosinophilia after BNT162b2 mRNA COVID-19 vaccination.
    Ishizuka K; Katayama K; Kaji Y; Tawara J; Ohira Y
    QJM; 2021 Dec; 114(10):745-746. PubMed ID: 34546346
    [No Abstract]   [Full Text] [Related]  

  • 15. Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia.
    Lyski ZL; Kim MS; Xthona Lee D; Raué HP; Raghunathan V; Griffin J; Ryan D; Brunton AE; Curlin ME; Slifka MK; Messer WB; Spurgeon SE
    Blood Adv; 2022 Feb; 6(4):1207-1211. PubMed ID: 34872103
    [No Abstract]   [Full Text] [Related]  

  • 16. Immediate reactions after mRNA SARS-CoV-2 vaccination.
    Jeimy S; Wong T; Song C
    CMAJ; 2021 Dec; 193(48):E1842. PubMed ID: 34772737
    [No Abstract]   [Full Text] [Related]  

  • 17. Multisystem inflammatory syndrome in children after BNT162b2 messenger RNA SARS-CoV-2 vaccination.
    Sakaida K; Iwashima S; Katsuki J; Sato K; Miyairi I
    Pediatr Int; 2023 Jan; 65(1):e15441. PubMed ID: 36513963
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
    Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Chen P; Söderdahl G; Österborg A; Smith CIE; Wullimann D; Vesterbacka J; Lindgren G; Blixt L; Friman G; Wahren-Borgström E; Nordlander A; Gomez AC; Akber M; Valentini D; Norlin AC; Thalme A; Bogdanovic G; Muschiol S; Nilsson P; Hober S; Loré K; Chen MS; Buggert M; Ljunggren HG; Ljungman P; Aleman S;
    EBioMedicine; 2021 Dec; 74():103705. PubMed ID: 34861491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comment on: Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series.
    Mungmunpuntipantip R; Wiwanitkit V
    Rheumatology (Oxford); 2021 Dec; 61(1):e29. PubMed ID: 34554230
    [No Abstract]   [Full Text] [Related]  

  • 20. Comment on: Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series: reply.
    Furer V; Zisman D; Elkayam O
    Rheumatology (Oxford); 2021 Dec; 61(1):e30. PubMed ID: 34554242
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.